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Abstract
Background: Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topical
steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema
(PCME) using a prospective, randomized, double-masked, placebo-controlled clinical study.
Methods: Eyes (1000) were randomized to placebo (497) or nepafenac 0.3% (503) used once daily, post-operatively
for 5 weeks at two ophthalmology clinics. Diagnosis of PCME was made by clinical, ocular coherence tomography
(OCT), and with fluorescein angiography confirmation. Correlation of PCME to NSAID use and the presence of
pre-operative risk factors for PCME were assessed including, contralateral PCME, diabetic retinopathy, retinal
vein occlusion, macular hole, epiretinal membrane, macular degeneration, retinal detachment repair, and
prostaglandin use.
Results: PCME was the most common complication associated with routine cataract surgery (4.2% with PCME
risk factors, 2.0% with risk factors excluded). Topical nepafenac 0.3% significantly reduces the incidence of PCME
compared to placebo when used after routine cataract surgery (p = .0001). When patients with pre-operative risk
factors are excluded, the incidence of PCME between treatment and placebo groups is equivalent (p = 0.31). PCME
relative risk (RR) was most significant in contralateral PCME (RR 19.5), diabetic retinopathy (RR 13.1), retinal vein
occlusion (RR 12.9), macular hole (RR 7.7), and epiretinal membrane (RR 5.7). Prostaglandin use and previous
retinal detachment were not shown to increase risk.
Conclusion: Pseudophakic cystoid macular edema is common after phacoemulsification cataract surgery.
Topical nepafenac 0.3% reduces PCME in patients with pre-operative risk factors for PCME compared to
placebo but shows no benefit in patients without pre-operative risk factors.
Trial registration: NIH ClincalTrials.gov retrospectively registered January 15, 2017, NCT03025945.
Background
Cataract surgery is one of the most commonly per-
formed surgeries. Although this procedure is generally
safe, the most common adverse event leading to postop-
erative vision loss is the development of pseudophakic
cystoid macular edema (PCME) [1]. The incidence of
clinically significant acute PCME (vision loss greater
than 20/40 from an expected 20/20, or equivalent)
ranges from 0.6 to 3.6% with a peak incidence at around
5 weeks after uncomplicated cataract surgery [1–3]. The
majority of PCME cases resolve spontaneously with
vision returning to normal [1, 2].
Clinically significant PCME includes ophthalmic and
angiographic findings with vision loss. A visual acuity of
20/40 best corrected visual acuity (BCVA) or less has
been considered clinically significant by most studies [4, 5].
The gold standard for identifying PCME has been with
fluorescein angiography and has yielded prevalences as
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high as 9.1 to 25.5% [2]. Findings of angiographic PCME do
not correlate well with vision loss. However, measurement
of macular thickness with optical coherence tomography
(OCT) does correlate well with visual impairment [6, 7].
The prevalent use of NSAIDs following cataract surgery
has evolved from the surgeons desire to reduce the inci-
dence of PCME which is the leading cause of decreased
visual acuity following an uneventful phaco-emulsification
cataract surgery [3]. Our unpublished survey of 62 cata-
ract surgeons indicates that 72% of those surveyed use
topical NSAIDs primarily to prevent PCME [Arizona Sur-
gical Eye Study: Survey of 62 U.S. cataract surgeons
regarding their use of topical NSAID’s following cataract
surgery May to July 2014, unpublished]. No ophthalmic
NSAID has a clinical indication for this use. Many studies
have shown a decrease in PCME from an angiographic or
OCT basis but not using a prospective design examining
clinically significant loss of vision [2, 3, 6, 8–10]. Also, no
prospective studies demonstrate significant differences in
the incidence of PCME with the use of NSAIDs, citing
insufficient sample size [4, 5, 11, 12].
There is evidence that topical NSAIDs reduce early
post-operative anterior segment inflammation [13, 14]. It
remains unknown whether NSAID use for four (4) weeks
translates into improved outcomes or overall comfort of
the patient [13, 14]. Studies have linked other benefits
such as decreased capsular phimosis and miosis [15].
PCME is thought to be due to disruption of the blood
aqueous and blood retinal barrier [16]. Although PCME
can occur in healthy eyes with no surgical complications,
risk factors increase the likelihood of it occurring. Risk
factors include PCME in the contralateral eye and any-
thing that may disrupt the blood retinal barrier such as
diabetes mellitus, uveitis, retinal vein occlusion, retinal
degeneration, macular degeneration, radiation retinopathy,
epiretinal membranes, choroidal tumors, prostaglandin
analog use, and aging [1]. Because PCME is largely
thought to be caused by an increase in prostaglandins,
NSAIDs are routinely used in the postoperative period to
inhibit cyclooxygenase (COX-1 and COX-2) enzymes,
which prevent the production of prostaglandins and their
downstream inflammatory effects [17–19].
Almeida et al. and Tzelikis et al. have prospectively
demonstrated negligible benefit with NSAID use after
uncomplicated cataract surgery in patients without risk
factors [4, 20]. Some literature supports the use of
NSAIDs in the treatment and prophylaxis of PCME in
uncomplicated surgical cases. Patients were compared
taking diclofenac 0.1% with patients taking fluorometho-
lone 0.1% as well as those taking prostaglandin analogs
and found that overall incidence of angiographic PCME
measured 5 weeks postoperatively was 54.7% in the ster-
oid group and 5.7% in the NSAID group [21]. Currently,
there is insufficient data defining the NSAID role in
treating acute PCME resulting in no standard protocol
at this time [22].
The presented independent, randomized, double blind,
prospective study evaluates the efficacy of post-operative
topical NSAIDs over a large sample size to prevent acute
PCME for routine cataract surgery. Included are the
common risk factors seen in clinical practice such as
contralateral PCME, prostaglandin analog use, diabetic
retinopathy, epiretinal membrane, macular degeneration,
previous retinal surgery, and retinal vein occlusion.
Methods
A prospective, randomized, double-masked, placebo-
controlled clinical trial was performed at two sites in
Tucson Arizona, as part of the Arizona Surgical Eye
Study (ASES). The ASES was an independent pro-
spective randomized study designed to examine the
incidence and causation of post cataract surgical com-
plications conducted from 10–15-2013 to 11–1–2015
stemming from NSAID use, phacoemulsification ma-
chine use, IOL type, and identified risk factors. The
ASES specifically examined complication type and in-
cidence, ocular discomfort, inflammation, capsular
phimosis, endothelial cell count change, and posterior
capsule opacification postoperatively. The clinical
evaluation described herein is a subset of the available
data at the time of publication examining solely the
incidence of PCME. The clinical trial was approved
by Western Independent Review Board. All patients
were treated according to the Declaration of Helsinki
document on human research ethics, and underwent
informed consent.
Study protocol
Subjects, 18 and older, were enrolled from the clinic.
The planned enrollment was 970 eyes (1000 completed)
for probable statistical significance with a 1:1 ratio of
control: treatment. Subjects were chosen from patients
who had visually significant cataracts and were to
undergo phacoemulsification with implantation of an
intracapsular positioned intraocular lens. Subject’s eyes
individually were randomly assigned by the compound-
ing pharmacy using random number generator in groups
of 10 to receive a placebo of sterile saline drops or nepa-
fenac 0.3%. Both study drops (nepafenac and placebo)
were produced individually by the pharmacy in a generic
bottle marked by a code and instructions for use. The
codes were maintained and utilized solely by the phar-
macy to determine the content of the bottle revealed
following the completion of the study. All patients re-
ceived topical prednisolone 1% four times daily for the
first week, tapered to 2 times daily over the second week
and 1 time daily for the subsequent 3 weeks which
approximates most common practice [1, 3, 4]. No
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additional steroids were used intraoperatively. Ofloxacin
0.3% was used 4 times daily for the first week and
discontinued.
In contrast to other studies, patients included those on
prostaglandins or on glaucoma medications, those with
an epiretinal membrane, macular degeneration, or dia-
betes mellitus (with or without retinopathy), macular
hole, previous retinal surgery, and history of central or
branch retinal vein occlusion. Glaucoma medication pa-
tients were included as a risk factor if the medications
were used any time prior to the surgery. Epiretinal mem-
branes were identified and included if seen on fundu-
scopic exam or OCT prior to cataract surgery within the
macula (central 5.5 mm diameter around the fovea or
2.75 disk diameters). Diabetic retinopathy was included
if there was any demonstrated evidence upon fundu-
scopic exam. Previous retinal surgery included any pa-
tient receiving any vitreoretinal procedure excluding
laser procedures. Macular holes, central and branch ret-
inal vein occlusions were included regardless of stage.
Exclusion criteria included previous uveitis (<1 year),
previous anterior segment intraocular surgery or a
hypersensitivity or allergy to NSAIDs. Any patients who
had a complicated cataract surgery (posterior capsule
rupture, vitreous loss, retained cortical material, signifi-
cant corneal edema or an IOL not placed in the capsular
bag) were excluded from the data analysis.
During the patient’s initial visit, information on demo-
graphics was obtained, including age, sex, birth date,
ethnicity, as well as ocular history and medical history.
The baseline exam included intraocular pressure, dilated
fundus exam, slitlamp exam and best-corrected visual
acuity (BCVA) by Snellen chart. Also, before surgery, a
trained technician performed a baseline OCT macular
cube scan (OCT protocol described below).
Three surgeons participated, LL, SM, and JL, with
similar methods and amount of time performing the sur-
gery. The surgeries were phacoemulsification cataract
extraction with posterior chamber in-the-bag IOL place-
ment. An equal number of patients (500 in each group)
were randomized in groups of 10 and underwent pha-
coemulsification cataract surgery with an Alcon (Fort
Worth, TX) Infinity machine using an SA60AT IOL and
an Abbott Medical Optics (Santa Ana, CA) WhiteStar
Signature using a ZCB00 IOL. Both the NSAID treat-
ment group and control group were equally divided
among the two phacoemulsification machines and their
respective IOL’s which was confirmed following the
study. Postoperatively, patients were routinely followed
up on day one, at 1 week and at 5 weeks. All visits in-
cluded a BCVA, slit lamp exam, IOP, and an OCT
macular cube scan. Subjects were assessed at all visits
for any postoperative inflammation, capsular phimosis
and posterior capsule opacification. During the study,
patients were interviewed about any issues or concerns
they had during that postoperative period including
medicine cost [19]. Any adverse events or complications
were followed closely and treated during the post-
operative period.
Once the two groups were randomized, one group re-
ceived one drop a day of nepafenac 0.3% for 5 weeks
which is the recommended dosage for the new higher
concentration nepafenac. Nepafenac ophthalmic suspen-
sion 0.3% was supplied as a sterile, aqueous suspension
with a pH approximately of 6.8. The osmolality of the
nepafenac 0.3% is approximately 300 mOsm/kg. Nepafe-
nac 0.3% contains: Active: nepafenac 0.3% Inactive: boric
acid, propylene glycol, carbomer 974P, sodium chloride,
guar gum, carboxymethylcellulose sodium, edentate dis-
odium, benzalkonium chloride 0.005%. The topical
NSAID was begun on the first post-operative day of sur-
gery. The other group received the placebo which were
buffered sterile saline drops with a pH approximately of
7.0 and osmolality of 290 mOsm/kg, dosed at the same
frequency. The placebo drops ingredients included: So-
dium chloride; Boric acid; calcium chloride; magnesium
chloride; potassium chloride; purified water; sodium bor-
ate; and carboxymethylcellulose sodium. The pharmacy
provided identical opaque generic bottles that were
coded with identification numbers only; no drug infor-
mation was visible on the bottle. The bottles also had a
patient identification number and expiration date dis-
played. Only the pharmacy retained the information for
the codes and this information was not shared with in-
vestigators until completion of the study. All participants
of the study also received prednisolone acetate 1% sus-
pension 4 times a day for 1 week, followed by 2 times a
day for 1 week, followed by 1 time daily for 3 weeks.
These medications were started on the day after the
surgery. Ofloxacin 0.3% drops were administered to all
participants and dosed at four times a day, starting one
day before surgery until 1 week after surgery.
Optical coherence tomography
OCT was performed on all subjects pre-operatively, at
1 week and at 5 weeks postoperatively. A spectral-
domain Cirrus HD-OCT device was used by experienced
staff who were also masked to treatment. The imaging
protocol utilized the OCT to measure macular volume
(VOL, mm [3]), central subfield thickness (CST, μm)
and average macular thickness (AVG,μm). For each sub-
ject, the best-quality macular images of all scans were
chosen and unreliable scans were excluded.
Study endpoint
Post-operative clinical findings of PCME within 6 weeks
including symptomatic or decreased BCVA and angio-
graphic as well as OCT corroboration to confirm the
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presence of PCME with experienced vitreo-retinal sur-
geons. Clinically significant PCME was defined as in-
cluding both: 1. A loss of two (2) lines of best corrected
visual acuity (BCVA) from the expected post cataract
BCVA (example: 20/40 BCVA from an expected 20/20
BCVA) or visually symptomatic distortion. 2. OCT, clin-
ical, and angiographic demonstrated PCME. All cases of
PCME were successfully treated by the retinal surgeon
with continuation of drops and subtenons injections of
steroids. Secondary outcome measurements included
ocular discomfort, inflammation as well as the compari-
son of ophthalmic medications for tolerability (COM-
TOL) questionnaire analysis. The intent-to-treat group
consisted of subjects who completed surgery, received
the study drugs and completed the follow-up. However,
any and all patients who received the study drugs were
included in the safety analysis. Complications and ad-
verse events were documented when interviewing the
participants or recorded by investigators. Adverse
events, for the purpose of this study, were defined as any
unintended or unwanted sign, symptom or clinical result
that could be associated with the study drugs.
Statistical analysis
The sample size using the Wald method was determined
prior to the study at approximately 485 in each group.
Given the likely incidence of clinically significant PCME
between 1 and 3% this sample size would likely lead to a
statistically significant outcome [18]. If no statistical dif-
ference was seen at this sample size, then it would be
expected that a routine cataract surgeon would not see
any difference in his patient outcomes in over 2 years of
surgery (@500 cases/year) [Arizona Surgical Eye Study:
Survey of 62 U.S. cataract surgeons regarding their use
of topical NSAID’s following cataract surgery May to
July 2014, unpublished]. A 35% increase in macular vol-
ume is considered to be significant by a previous study
and was used as our threshold for the OCT measures
[10]. Comparison of OCT’s between five (5) weeks and
baseline macular volumes were performed within sub-
jects using a 2-way ANOVA (p = .05) between subjects
in placebo and treatments groups. Two additional 2-way
ANOVAs were also completed within subjects pre-op
and 5-week OCTs between placebo and treatment
groups, both with and without risk factors. As men-
tioned previously, a loss of more than 2 lines of
expected BCVA with angiographic evidence of CME was
used to define “clinically significant” PCME. The inci-
dence of clinically significant PCME with both NSAID
nepafenac 0.3% treatment and control was determined
and compared with Chi-squared (Dof = 1) tests with all
patients and both including and excluding risk factors.
An odds ratio or relative risk of probable PCME was cal-
culated for each of the identified risk factors by
comparing the ratio of the incidence of PCME found
with each risk factor to the baseline incidence of PCME
without risk factors. Lastly, a logistical regression ana-
lysis was completed to examine the probability of mul-
tiple other factors (such as IOL type, phaco machine
used) affecting the outcome of the study.
Results
Six hundred and sixty two (662) patients, one thousand
eyes (1000), completed the study (1007 eyes enrolled).
Two patients had intraoperative complications and were
withdrawn from the study. One patient withdrew volun-
tarily due to drop intolerance. Four patients were lost to
follow-up.
Pseudophakic cystoid macular edema (PCME) was
the most common complication following cataract sur-
gery at 4.2% with careful diagnosis. The Incidence of
PCME was 2.1% with pre-operative risk factors ex-
cluded. All cases of PCME resolved with treatment.
The next highest pseudoemulsification related compli-
cations were persistent iritis (0.4%), posterior capsular
rupture (0.2% - excluded from this study) and persistent
corneal edema (0.1%). Complications did not statistically
correlate with PCME in this study. Five hundred three
(503) patients had cataract surgery with an Alcon Infinity
pseudoemulsification machine and a SA60AT implant (Ft.
Worth, TX). Four hundred ninety seven (497) patients
had cataract surgery with an Abbott Medical Optics
WhiteStar Signature pseudoemulsification machine and a
ZCB00 implant (Irvine, CA). The incidence if PCME was
21 in each surgical equipment/implant group. Risk factors
were also equally divided in the groups.
Results of PCME between nepafenac 0.3% and placebo
groups using the Chi-squared tests were subdivided into
all patients, those with risk factors and those without
risk factors. Table 1 shows the results of the PCME Chi-
squared probable significance test.
Comparison of macular volume was completed with
OCT measurement pre-op to 5 weeks post-op examin-
ing nepafenac 0.3% and with placebo groups. The 2-Way
ANOVA in Table 2 indicates significantly increased
macular volume post-operatively in all patients. Treat-
ment with nepafenac 0.3% when compared to placebo
was only statistically significant in patients who had risk
Table 1 PCME incidence Chi-squared significance
Patient group Patients PCME Chi- Squared (p=)




NSAID use null probable
significance (p<0.05)
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factors. Figures 1 and 2 depict the changes in post-
operative macular volume from the pre-operative meas-
urement comparing the use of nepafenac 0.3% to placebo
with a 95% confidence interval. This also confirms the
findings from the 2-way ANOVA tests.
The relative risk of developing PCME was calculated
for each of the eight identified risk factors to quantify
their significance in terms of probable PCME for the
clinician. Each risk factor was statistically equally dis-
tributed between the nepafenac and placebo groups.
Table 3 illustrates the incidence of PCME with each
risk factor and relative risk in terms of an odds ratio.
The highest risk groups were those with PCME in the
previously operated eye, those with diabetic retinop-
athy, and those with a vein occlusion. Interestingly both
macular degeneration and prostaglandin use showed a
negligible increased risk of developing PCME. No pa-
tients with previous retinal detachment repair devel-
oped PCME.
Additional PCME contributing factors were analyzed
using a binary logistical regression. Factors included:
Gender, age, ethnicity, IOL type, phacoemulsification
machine, NSAID use, and Risk factor presence. The
results confirmed the previous findings in that the pre-
dominant factors were pre-operative risk factors followed
by nepafenac use. NSAID use and presence of a pre-
operative risk factor significantly outweighed the other
potential factors. Table 4 are the calculated binary logis-
tical regression coefficients for each factor.
Discussion
The new higher concentration topical nepafenac 0.3%
dosed once daily reduces PCME in patients with pre-
operative risk factors for PCME compared with placebo but
shows no benefit in patients without pre-operative risk fac-
tors. Pseudophakic cystoid macular edema is common after
phacoemulsification cataract surgery and its prevention is
the practitioner’s primary reason for post-operative NSAID
use [Arizona Surgical Eye Study: Survey of 62 U.S. cataract
surgeons regarding their use of topical NSAID’s following
cataract surgery May to July 2014, unpublished]. There is a
potential for reduced NSAID utilization if its use is limited
to cataract surgery patients with pre-operative risk factors
for PCME as identified by their relative risk.
While the present independent study examined nepa-
fenac 0.3% dosed once daily, it is reasonable that the re-
sults can be extrapolated to topical NSAID’s in general.
The findings are consistent with other studies examining
other topical NSAIDs reducing the incidence of macular
thickening compared to placebo [4–6].
This study is part of the larger Arizona Surgical Eye
Study (ASES) which also examines the other post-
operative uses of nepafenac 0.3% as well as surgical
equipment, IOL type and complications. These other
results were not included in this publication except to
insure they did not have an effect on PCME. The negli-
gible effect on PCME by other variables in the ASES
study was demonstrated by the binary logistical regression
Table 2 2 Way ANOVA examining intra-subject macular volume
change pre-op and 5 weeks post-op, also between NSAID and
placebo groups with all patients and with those having risk
factors
2-Way ANOVA with replication
All patients macular volume P-value
Post-operative volume change 0.032
NSAID vs. placebo volume change 0.858
Patients with Risk Factors macular vol. P-value
Post-operative volume change 0.003
NSAID vs. placebo volume change 0.031
Fig. 1 Post-operative change in macular volume in patients without risk factors (95% CI)
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analysis. There may be other combined effects of nepafe-
nac which make its routine use beneficial beyond the
development of PCME, such as its clinical indication of
reducing post-operative inflammation.
A higher than expected incidence of PCME was
noted at 4.2%. The authors see this as a result of the
high incidence of risk factors, approximately 30%, and
the inclusion of pre-operative risk factors in the study
[18]. If risk factors are excluded the incidence of
PCME is 2.1% which is consistent with previous stud-
ies. The relative risk of PCME with pre-operative risk
factors is also consistent with a recent large retro-
spective study [23]. The presence of increased macu-
lar volume post-operatively also is consistent with
previous studies [4].
The new higher concentration nepafenac 0.3% dosed
once daily, appears well tolerated. No adverse events
were found with the medication even at its higher
concentration (0.3%) and it was found to be safe for
routine use in post-operative pseudoemulsification pa-
tients. These findings are similar to other studies exam-
ining the lower dose nepafenac 0.1% administered 3
and 4 times daily [17, 18].
The continued ASES study may substantiate the use of
NSAIDs adjunctively in reducing inflammation in the
first post-operative week [13, 14]. Anti-inflammatory
benefit may exist beyond the first week but this re-
mains to be determined by subsequent analysis of the
collected data.
Conclusions
The results of this non-industry supported, large, pro-
spective, double-blind study assist the practicing oph-
thalmologist in deciding the appropriate use of topical
NSAIDs in the prevention of PCME. Based upon the
study’s results, the ophthalmic community, with discretion,
could elect to alter the present practice patterns main-
taining or improving patient outcomes while potentially
reducing NSAID use.
Fig. 2 Post-operative change in macular volume in patients with risk factors (95% CI)
Table 3 Risk factor odds ratio (relative risk) of developing PCME
Risk factor odds ratio PCME PCME Odds ratio





to no risk factor (95% CI)
PCME Contralateral Eye 11 42.3 19.5 (18.5–20.6)
Diabetic Retinopathy 19 28.4 13.1 (12.3–13.9)
Vein Occlusion CRVO/
BRVO
3 27.3 12.6 (9.0–16.2)
Macular Hole 3 16.7 7.7 (5.7–9.7)
Epiretinal Membrane 7 12.3 5.6 (4.7–6.8)
Prostaglandin Use 1 3.6 1.6 (0.1–3.16)
Macular Degeneration 3 3.1 1.4 (0.6–1.8)
All Risk factors 42 13.6 6.3 (4.9–7.6)
Table 4 Binary logistical regression factor coefficients for
possible PCME contributing factors
Factor Coefficient Value
IOL/Phaco Machine b1 0.19
NSAID use b2 1.32
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